LIBRETTO-431
Proved that a RET pill is better than chemotherapy with or without immunotherapy as first treatment for RET-fusion lung cancer.
261 patients. PFS 24.8 vs 11.2 months (HR 0.46); intracranial responses in 82% vs 58%. Reinforces the rule that oncogene-addicted NSCLC should receive targeted therapy before immunotherapy.
- Median 24.8 vs 11.2 months with Selpercatinib compared with Platinum-pemetrexed ± pembrolizumab; about 13.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 54 percent lower chance of the event at any given time (hazard ratio 0.46, likely range 0.31 to 0.7).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: First-line RET-fusion advanced NSCLC: selpercatinib vs platinum-pemetrexed ± pembrolizumab. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (RET); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
261 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR), ITT-pembrolizumab populationprimary | Selpercatinib | 129 | 24.8 months | 0.46 (0.31–0.7) | <0.001 | link |
| Platinum-pemetrexed ± pembrolizumab | 83 | 11.2 months |
Pages like this
not linked directly; found by shared links- ProductVandetanib
Shares LIBRETTO-531, RET.
- ProductPralsetinib
Shares Selpercatinib, RET, Non-small-cell lung cancer.
- PersonKoichi Goto
Shares Selpercatinib, RET, Non-small-cell lung cancer.
- PersonAlexander Drilon
Shares Selpercatinib, RET, Non-small-cell lung cancer.
- PersonTakashi Kohno
Shares RET, Non-small-cell lung cancer.
- TrialCROWN
Shares Sequence: targeted therapy before immunotherapy in driver-positive NSCLC, Non-small-cell lung cancer.
- PersonJustin F. Gainor
Shares RET, Non-small-cell lung cancer.
- InstitutionKyushu University Hospital
Shares RET, Non-small-cell lung cancer.